Vergenix STR aggregates cross linked rhCollagen with platelet-rich plasma (PRP), which is a concentrated blood plasma derived from the patient's own blood that contains high levels of platelets.
Platelets comprise of growth factors that can stimulate tissue generation and repair, including soft tissue repair, bone regeneration, development of new blood vessels, and stimulation of the healing process.
Once administered, the Vergenix STR will act as a scaffold to support cell adhesion and proliferation involved in the tendon healing while preserving growth factor containing PRP in the vicinity of the injury.
The product forms a viscous gel matrix following injection into the affected area, helping to hold the platelet concentrate in place.
Later, the matrix will release growth factors in a controlled manner with assured biodegradation time to enable tissue repair.
CollPlant CEO Yehiel Tal said: “In the past few months, we have shown that treatment with our product provides for substantially superior results when compared to published steroid treatment results, the current standard of care for tendinopathy.
“We are presently in dialogue with potential distributers for product marketing in Europe and expect initial sales within the coming months.
“Of note, this is the second CE Mark the company received this year, with the first granted at the beginning of the year, to its VergenixFG product, indicated for the treatment of chronic and surgical wounds.”
CollPlant is engaged in the development and commercialization of tissue repair products for orthobiologics and wound care markets.
